StablevaX™ is a novel and disruptive technology that aims to produce Fridge Free vaccines to eliminate the need for the global Cold Chain, reduce vaccine wastage and save lives through better immunisation

Stablepharma completes first close of Series A raise with £2 million following announcements of high-profile partnershipsFridge-Free Covid-19 Vaccines a possibility with Stablepharma Technology - see news section

StablevaX™ - a vital complementary technology for vaccines

Our novel patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. Stablepharma has developed a stabilised vaccine solution that could eliminate the need for the cold chain and enable stockpiling anywhere in the world.

StablevaX™ is designed to dramatically enhance the performance of existing and new vaccines. Stablepharma stands to revolutionise the vaccine industry, by helping shield vaccines from temperature-related deterioration and wastage.

StablevaX™ has shown strong in-vitro and in-vivo data on stabilising range of vaccines including Tetadif (Td) and naked COVID mRNA. Stablepharma R&D team believe that the StablevaX™ technology could be applicable to over 60 vaccines.

Latest Press Coverage StablevaX™

Daniela Maria Briceño Garcia joins the Stablepharma Science Team
Fridge-Free Covid-19 Vaccines a Possibility with Stablepharma Technology
Stablepharma appoint two new members to the team in the UK and the R&D site in Madrid.
Stablepharma’s mission to eliminate the cold chain – an interview by Health Tech World
Stablepharma and BB-NCIPD Ltd (Bul Bio) Accelerate Vaccine Development with Collaboration
Stablepharma completes the first close of Series A raise with £2 million following a number of high-profile partnership announcements
Alan Boyd, of Boyd Consultants & Advisor to Stablepharma, talks about his work, collaborations and the impact of the Pandemic
Özgür Tuncer CEO talks about Developing Thermostable Vaccines To Improve Accessibility Worldwide
Stablepharma partners with the University of Strathclyde to advance their COVID mRNA vaccine thermo-stabilisation technology
Stablepharma appoints Professor Saul Faust to the Advisory Board
Stablepharma Response
Stablepharma awarded £50,000 as part of UK research and innovation program

The WHO state that roughly 50% of vaccines are wasted due mostly to failures in the cold chain. Stablepharma aims to ensure that all vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature.

Stablepharma Technology

Stablepharma Technology

StablevaX™ is a patented product that aims for enhanced thermostability, following WHO protocols

Zero Refrigeration

Zero Refrigeration

StablevaX™ technology aims to eliminate the need for refrigeration

Thermostable Vaccines

Thermostable Vaccines

StablevaX™ technology is designed with the aim of administering to patients without any change to current practice


Our white paper

StablevaX™ - a complementary technology for COVID-19 vaccines

In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never been starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.

Download
StablevaX™ - a complementary technology for COVID-19 vaccines

Receive our investor information pack

Please enter your details below to receive our investor information pack